

Stockholm, 24 april 2020 (NYSE: VNE och SSE: VNE-SDB)

Kvartalsrapport januari – mars 2020

Finansiell sammanfattning kvartal 1 2020

- Underliggande finansiellt resultat bättre än förväntat, tack vare våra marknadsanpassningsinitiativ (MAI)
- Nettoomsättning 362 MUSD
- Nettoomsättningen minskade 27%, inkl. organisk försäljning¹⁾ som minskade 15%, 9 procentenheter bättre än den globala fordonsproduktionen
- Försäljningen för Aktiv Säkerhet minskade 15%, inkl. organisk försäljning¹⁾ som minskade 13%
- Operativt kassaflöde, neg 9 MUSD

Utsikter för 2020

- Drar tillbaka tidigare indikation för organisk försäljning för helåret 2020, förväntas dock överträffa den globala fordonsproduktionen drivet av nylanseringar
- Valutaomräkningseffekt väntas vara negativ på ca 2%
- FoU, netto, väntas förbättras med cirka 100 MUSD från 2019 för jämförbara enheter
- Kassaflöde före finansiering¹⁾ väntas (för jämförbara enheter) förbättras betydligt och rörelseförlusten minska från 2019 års nivåer tack vare framgångsrika marknadsanpassningsinitiativ

Viktiga händelser i verksamheten

- Nettokassan steg till 970 MUSD tack vare starkt underliggande kassaflöde och intäkter från avyttringen av den asiatiska delen av VNBS
- Marknadsanpassningsinitiativ bidrog till bättre kassaflöde före finansiella aktiviteter¹⁾ än förväntat på 124 MUSD
- Ytterligare initiativ initieras för att mildra COVID-19 pandemins påverkan på vårt kassaflöde och resultat
- Orderingången för första kvartalet 2020 uppgick till cirka 175 MUSD i genomsnittlig årlig försäljning, mer än 50% var Aktiv Säkerhet
- Veoneer och Volvo Cars överens om att dela JV Zenuity, så att respektive företag kan fokusera på sina strategiska prioriteringar
- Veoneer avslutar strategisk översyn av verksamheten för bromssystem: Tillgångarna i VBS USA redovisas som tillgångar som innehas för försäljning

Nyckeltal

(Milj. USD / %)	jan-mars								
	2020		2019		förändr	rull 12 mån		jan-dec 2019	
	\$	%	\$	%	\$	\$	%	\$	%
Nettoomsättning	\$ 362		\$ 494		\$ (132)	\$ 1,770		\$ 1,902	
Bruttovinst / Marginal	\$ 53	14.5 %	\$ 85	17.2 %	\$ (32)	\$ 279	15.8 %	\$ 311	16.4 %
RD&E, netto / % av nettoomsättning	\$ (131)	(36.1)%	\$ (156)	(31.5)%	\$ 25	\$ (537)	(30.3)%	\$ (562)	(29.6)%
Rörelseresultat / Marginal	\$ (122)	(33.8)%	\$ (128)	(25.9)%	\$ 6	\$ (454)	(25.6)%	\$ (460)	(24.2)%
Kassaflöde från den löpande verksamheten	\$ (9)		\$ (90)		\$ 81	\$ (244)		\$ (325)	

Kommentar från Jan Carlson, styrelseordförande, verkställande direktör och koncernchef

Coronavirusets spridning är i första hand en global hälsokris och våra tankar går till alla runt om i världen som lider av dess konsekvenser. För oss på Veoneer är hälsa och säkerhet vår främsta prioritering och vi vidtar nödvändiga åtgärder och steg för att skydda våra medarbetare och vår verksamhet.

Under kvartalet har vi lyckats kombinera nödvändiga åtgärder inom hälsa- och säkerhet med ett starkt affärsmässigt agerande. Trots låga affärsvolymerna lyckades vi förbättra i princip samtliga områden som ligger inom vår kontroll. Vår kassabalans ökade till 970 MUSD, vårt rörelsekapital netto ökade med 89 MUSD, FoU sjönk med 25 MUSD och investeringarna sjönk med 32 MUSD. Vi har också varit snabba med att anpassa vårt arbetssätt, till exempel arbetar 4100 medarbetare hemifrån utan tekniska problem. Som svar på krisen har vi till dags dato dessutom på olika sätt minskat vår personalstyrka med omkring 200 personer och ytterligare motsvarande runt 1000 heltidstjänster omfattas av någon typ av arbetsmarknadsåtgärder. Även om det är tungt att fatta sådana beslut kommer vi även framgent genomföra de åtgärder som krävs för att vi ska ta Veoneer genom krisen.

De goda resultat vi uppnått detta mycket ovanliga kvartal kommer från ett starkt fokus från samtliga medarbetare på verksamheten i sig och en anpassning till den pågående krisen. Jag vill ta tillfället i akt att tacka hela Veoneers team för deras engagemang och starka insatser denna tuffa tid.

Den strategiska översyn som kommunicerades för första gången under 2019 har slutförts och Veoneer är nu helt inriktat mot att bygga ett världsledande hård- och mjukvarubolag inriktat mot s.k. *collaborative driving* inom fordons säkerhet. Delningen av Zenuity och införlivandet av mer än 200 duktiga Zenuity-medarbetare till Veoneers Systems & Software Group kommer innebära att vi stärker vår integrations- och systemkapacitet inom detta område. Förflyttningen av bromskontrollverksamheten till en väletablerad leverantör i bilbranschen ger oss möjlighet att fullt ut fokusera på våra kärnaktiviteter, förvissade om att både vår kund och våra medarbetare inom bromssystem kommer till ett bra nytt hem.

2020 fortsätter vara ett betydelsefullt lanseringsår för Veoneer och medan några kundlanseringar kommer senareläggas, fortgår våra leveranser av nya teknologier till ett flertal nya fordonsplattformar i god takt.

Vi är på god väg att uppnå den balans vi eftersträvar där Veoneer är mer effektivt och hanterar konsekvenserna från krisen samtidigt som vi förstärker företagets kärnteknologier och produkter. Trots betydligt lägre volymer än förväntat, förväntar vi oss att under 2020 kunna reducera våra kostnader för FoU betydligt, minska vår rörelseförlust och vårt negativa kassaflöde.

Fordonsindustrin genomgår en tuff tid, men tack vare långsiktiga ansträngningar från hela vårt team är vi idag ett starkare och mer fokuserat företag.

Övriga sidor i rapporten publiceras enbart på engelska.

En telefonkonferens hålls idag, fredag 24 april 2020 kl 13:00 CET. Se www.veoneer.com för kod och telefonnummer. Presentationen publiceras på hemsidan innan telefonkonferensen börjar. Se även Non-U.S. GAAP Financial Measures på sid 9 i denna kvartalsrapport. Ej U.S. GAAP samt övrigt markerat med **, se jämförelsetabell samt Non-U.S GAAP Financial Measures på sid 8 i denna kvartalsrapport, angående organisk försäljning, vilken är framåtblickande och inte baseras på U.S. GAAP (god redovisningssed i USA).

Financial Overview for the Quarter

Sales by Product

Net Sales Dollars in millions, (except where specified)	Three Months Ended March 31				Components of Change vs. Prior Year					
	2020	2019	U.S. GAAP Reported		Currency		Divestiture		Organic ¹	
	\$	\$	Chg. \$	Chg. %	\$	%	\$	%	\$	%
Restraint Control Systems	162	215	(53)	(25)	(5)	(2)	—	—	(48)	(23)
Active Safety	163	192	(29)	(15)	(5)	(2)	—	—	(24)	(13)
Brake Systems	37	87	(50)	(57)	—	—	(46)	(53)	(4)	(4)
Total	\$ 362	\$ 494	\$ (132)	(27)%	\$ (10)	(2)%	\$ (46)	(10)%	\$ (76)	(15)%

¹ Non-U.S. GAAP measure reconciliation for Organic Sales

Net Sales - Veoneer's net sales for the quarter declined by 27% to \$362 million as compared to 2019. Organic sales¹ declined by 15%, as compared to the drop in LVP of 24% for the quarter. The remainder of the decline was from currency translation effects of 2% and VNBS-Asia divestiture of 10%. During the quarter, our organic sales developed essentially in-line with our expectations, until mid-March when the COVID19 pandemic affected our sales.

Sequentially, from the fourth quarter in 2019, net sales decreased \$94 million or 21%, mostly due to the VNBS-Asia divestiture effect \$58 million. In addition RCS declined \$35 million due the LVP decline. This was partially offset by an increase in Active Safety of \$17 million.

Restraint Control Systems - Net sales for the quarter of \$162 million decreased by 25% as compared to 2019. The organic sales decline of 23% was primarily due to the LVP drop driving lower volumes in China, South Korea, and North America.

Income Statement

Gross Profit - The gross profit for the quarter of \$53 million was \$32 million lower as compared to 2019, where the negative LVP, volume and product mix effects that caused the lower organic sales were the main contributors. Net currency effects on the gross profit were negligible, while the impact from the VNBS-Asia divestiture was \$(6) million.

Operating Loss - The operating loss for the quarter of \$122 million decreased by \$6 million as compared to 2019, despite the decline in organic sales. The benefit of the VNBS-Asia divestiture was \$8 million.

The RD&E, net of \$131 million decreased \$25 million as compared to 2019, due to lower gross costs and higher engineering reimbursement. The benefit of the VNBS-Asia divestiture was \$8 million.

The SG&A expense of \$44 million for the quarter decreased by \$8 million as compared to 2019, primarily due to lower consultancy and IT costs, and includes a \$3 million benefit related to the VNBS-Asia divestiture.

Other income and amortization of intangibles combined were \$5 million lower for the quarter as compared to 2019 mainly due to lower amortization of intangibles including \$2 million related to VNBS-Asia divestiture. Net currency effects on the operating loss were \$4 million favorable for the quarter as compared to 2019.

Cash Flow and Balance Sheet

Net cash used in operating activities - Net cash used in operating activities of \$9 million during the quarter was \$81 million favorable as compared to 2019. The improvement was driven by net working capital¹ of \$89 million, partially due to the timing effects from Q4'19.

Net cash proceeds from investing activities - Net cash proceeds from investing activities of \$133 million during the quarter was \$187 million higher as compared to 2019. This was due to lower capital expenditures of \$32 million and the VNBS-Asia divestiture of \$176 million.

Cash flow before financing activities¹ - The cash flow before financing activities of \$124 million for the quarter was \$268 million higher as compared to 2019 mainly due to improved net working capital, lower capital expenditures and the VNBS-Asia divestiture.

Active Safety - Net sales for the quarter of \$163 million decreased by 15% as compared to 2019. This decline was primarily driven by the organic sales decline of 13%. This out-performance versus the LVP was driven by our strong product content on premium brands in Europe, where we have a relatively higher CPV than in other markets.

Strong demand for mono, stereo and thermal camera systems and ADAS ECUs on several models drove an increase in organic sales. This growth was more than offset by the volume effect from the product mix shift from our 24Ghz to 77Ghz radar technology and the phase-out of certain mono-vision programs with BMW, and lower underlying LVP.

Brake Systems - Net sales for the quarter of \$37 million decreased by 57% as compared to 2019. The organic sales decline of 4% was much better than the LVP decline. In addition, the VNBS-Asia divestiture accounted for a 53% decline or \$46 million.

Net Loss - The net loss for the quarter of \$231 million increased by \$83 million as compared to 2019, primarily due to the combined \$67 million net loss, due to the divestiture of VNBS-Asia \$77 million gain, and the impairment of VBS-US assets held for sale of \$(144) million. The equity method investment loss increased \$1 million as compared to 2019.

The interest expense, net for the quarter was \$4 million lower as compared to 2019, due to interest expense related to the convertible debt of \$4 million.

Income tax expense of \$23 million for the quarter was \$17 million higher as compared to 2019. This is mainly due to the \$21 million of discrete tax expense related to the VNBS-Asia divestiture.

The non-controlling interest expense of \$2 million in the VNBS JV for the quarter was \$13 million unfavorable as compared to 2019. This is due to VBS-US being excluded from non-controlling interest and the VNBS-Asia divestiture in February 2020.

Loss per Share - The loss per share of \$2.09 increased for the quarter as compared to a \$(1.57) in 2019. This decline was mainly due to the combined net loss of \$0.60 per share from the VNBS-Asia divestiture gain, and VBS-US write-down. The share count increase from the common stock issuance in 2019 reduced the loss by \$0.52 per share.

Net Working Capital¹ - The positive change in net working capital of \$89 million for the quarter was partially due to the \$30 million reversal of timing effects at year-end, further improvements in receivables, net and proactive inventory management related to the COVID-19.

Capital Expenditures - Capital expenditures of \$27 million for the quarter decreased by \$32 million as compared to 2019 mainly due to lower investments in VBS-US, facility expansions, engineering related IT. The benefit of the VNBS-Asia divestiture was \$6 million.

Cash and cash equivalents - Cash and cash equivalents of \$970 million for the quarter, increased by \$111 million during the quarter, mainly due to the cash flow before financing activities.

Segment Overview for the Quarter

Electronics

Dollars in millions, (except where specified)	Three Months Ended March 31						Components of Change vs. Prior Year			
	2020		2019		U.S. GAAP Reported		Currency		Organic ¹	
	\$	%	\$	%	Chg. \$	Chg. %	\$	%	\$	%
Net Sales	\$ 325		\$ 407		\$ (82)	(20)%	\$ (10)	(2)%	\$ (72)	(18)%
Operating Loss / Margin	\$ (94)	(29.0)%	\$ (90)	(22.1)%	\$ (4)					
Segment EBITDA¹ / Margin	\$ (72)	(22.2)%	\$ (71)	(17.3)%	\$ (1)					
Associates	7,178		7,716		(538)					

¹ Non-U.S. GAAP measure reconciliation for Organic Sales and Segment EBITDA

Net Sales - The net sales for the Electronics segment decreased by \$82 million to \$325 million for the quarter as compared to 2019. This sales decline was mainly due to the organic sales¹ decline in Active Safety and Restraint Control Systems of \$24 million and \$48 million, respectively, along with the currency translation effects of \$10 million.

Operating Loss - The operating loss for the Electronics segment of \$94 million for the quarter increased by \$4 million as compared to 2019, mainly due to the reduction in RD&E, net which was more than offset by the negative volume and product mix effects causing the lower organic sales in Active Safety and Restraint Control Systems.

EBITDA¹ - The segment EBITDA¹ loss for Electronics increased by \$1 million to negative \$72 million for the quarter as compared to 2019. This change is mainly due to the increase in operating loss for the segment while depreciation and amortization increased by \$3 million.

Associates - Associates in the Electronics segment decreased by 538 net to 7,178 as compared to 2019, mainly due to a reduction in engineering of ~400 and direct labor of ~250. Temporary associates decreased by ~240 reflecting the volume decline as compared to 2019.

Deliveries - The quantities delivered during the quarter were 3.7 million units for Restraint Controls Systems and 1.9 million units for Active Safety.

Brake Systems

Dollars in millions, (except where specified)	Three Months Ended March 31						Components of Change vs. Prior Year					
	2020		2019		U.S. GAAP Reported		Currency		Divestiture		Organic ¹	
	\$	%	\$	%	Chg. \$	Chg. %	\$	%	\$	%	\$	%
Net Sales	\$ 37		\$ 87		\$ (50)	(57)%	\$ -	0 %	\$ (46)	(53)%	\$ (4)	(4)%
Operating Loss / Margin	\$ (13)	(34.5)%	\$ (19)	(21.8)%	\$ 6							
Segment EBITDA¹ / Margin	\$ (12)	(31.8)%	\$ (10)	(11.6)%	\$ (2)							
Associates	351		1,430		(1,079)							

¹ Non-U.S. GAAP measure reconciliation for Organic Sales and Segment EBITDA

Net Sales - The net sales for the Brake Systems segment decreased by \$50 million to \$37 million for the quarter as compared to 2019. The sales decrease was mainly attributable to the VNBS-Asia divestiture of \$46 million.

Operating Loss - The operating loss for the Brake Systems segment for the quarter decreased to \$13 million from \$19 million as compared to 2019. This change was mainly due to the divestiture of VNBS-Asia where the loss in 2019 was \$7 million for the quarter.

EBITDA¹ - The segment EBITDA loss for Brake Systems increased by \$2 million to negative \$12 million for the quarter as compared to 2019. This change was mainly due to the net effect of the VNBS-Asia divestiture.

Associates - The number of associates in the Brake Systems segment decreased by 1,079 to 351 net as compared to 2019, mainly due to the divestiture of VNBS-Asia.

Deliveries - The quantities delivered during the quarter were 0.2 million units for the Brake Systems.

Corporate and Other

Dollars in millions, (except where specified)	Three Months Ended March 31					
	2020		2019		U.S. GAAP Reported	
	\$	%	\$	%	Chg. \$	Chg. %
Net Sales	\$ -		\$ -		\$ -	
Operating Profit (Loss) / Margin	\$ (15)	- %	\$ (19)	- %	\$ 4	
EBITDA¹ / Margin	\$ (15)	- %	\$ (18)	- %	\$ 3	
Associates	42		46		(4)	

¹ Non-U.S. GAAP measure reconciliation for EBITDA

Operating Loss and EBITDA¹ - The operating loss and EBITDA for Corporate and other for the quarter decreased to \$15 million from an operating loss of \$19 million and EBITDA \$(18) million as compared to 2019. This decrease was mainly due to process improvements and lower consultancy and IT support costs.

Associates - The number of associates decreased by 4 to 42 for the quarter as compared to 2019 due to a reduction in temporary associates related to process improvements of being a standalone company.

The Veoneer associates and financial figures for the quarter are comparable to 2019 as the second quarter in 2018 was the last quarter of carve-out reporting.

Veoneer Nissin Brake Systems VNBS-Asia (China and Japan)

Historical Figures Dollars in millions, (except where specified)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Full Year		
	2020	2019	2018	2019	2018	2019	2018	2019	2018	2019	2018
Net Sales	\$ 24	\$ 72	\$ 99	\$ 81	\$ 96	\$ 77	\$ 85	\$ 84	\$ 90	\$ 313	\$ 370
Gross Profit	\$ 4	\$ 10	\$ 15	\$ 13	\$ 16	\$ 12	\$ 14	\$ 16	\$ 16	\$ 50	\$ 61
SG&A	\$ (1)	\$ (4)	\$ (4)	\$ (4)	\$ (4)	\$ (14)	\$ (4)	\$ (3)	\$ (4)	\$ (25)	\$ (15)
RD&E	\$ (1)	\$ (9)	\$ (6)	\$ (7)	\$ (5)	\$ (6)	\$ (7)	\$ (6)	\$ (7)	\$ (28)	\$ (25)
Operating Income / (Loss)	\$ 1	\$ (7)	\$ 2	\$ (2)	\$ 4	\$ (11)	\$ —	\$ 2	\$ 2	\$ (18)	\$ 7
Capital Expenditures	\$ 1	\$ 7	\$ 3	\$ 10	\$ 5	\$ 5	\$ 5	\$ 3	\$ 7	\$ 26	\$ 19
Depreciation and Amortization	\$ (3)	\$ (8)	\$ (8)	\$ (7)	\$ (8)	\$ (7)	\$ (8)	\$ (7)	\$ (8)	\$ (30)	\$ (32)
Associates - TOTAL		1,093	1,133	1,080	1,157	1,095	1,125	1,074	1,113		
Associates - Direct Labor		522	571	519	582	543	546	522	541		
Associates - RD&E		225	222	216	226	219	225	220	221		
Associates - Temporary		164	173	171	192	200	145	179	160		

VNBS Summary

The divestiture of the VNBS JV Asia (China and Japan) was completed on February 3, 2020 resulting in net cash proceeds of \$167 million and a gain on the divestiture of \$77 million. As illustrated above, the 2019 Net sales of \$313 million generated an operating loss of \$18 million with capital expenditures of \$26 million, and depreciation and amortization of \$30 million. The divestiture included 1,074 associates.

COVID-19 Commentary

The situation created by the COVID-19 pandemic has led to an unprecedented economic uncertainty globally. This includes the automotive industry and the LVP for 2020. We have been more conservative with our contingency planning assumptions than the April industry estimate from IHS which assumes a year over year decline of approximately 21%.

As noted in our 2020 Outlook, in response to the pandemic, the Company has additional Market Adjustment Initiatives underway to further mitigate the impact on its cash levels. Veoneer estimates the organic sales impact from the lower customer demand to be approximately \$33 million for the first quarter. In the first quarter, despite the severe downturn, Veoneer reduced its cash consumption, and the MAIs contributed approximately \$25 million to our first quarter operating results.

The Company intends to continue to extend its market adjustment initiatives to further mitigate the impact of the pandemic on its cash flow and operating results. This includes reducing its annual RD&E, net by an approximately \$100 million, as well as other expenses with the intention of reducing its operating loss and conserving cash in 2020 so as to enter 2021 in a stable cash position.

Toward the end of the first quarter 2020, Veoneer saw many of its OEM customers in North America and Europe halt production, while China, S. Korea and the Rest of Asia slowly began to restart production, although still well below pre-crisis levels. As a health priority and in response to the customer production schedules, Veoneer also halted or reduced production in all locations. Currently our OEM customers in North America and Europe are essentially shut-down through April and are planning for a staggered recovery during May, while China is returning to high production levels and production in the Rest of Asia is higher than in Europe and the US, albeit not at China levels.

As our OEM customers return to production in the upcoming weeks and months, we are preparing to return to production as well, taking additional precautions to ensure the safety of our workers in each of our facilities, in accordance with detailed developed protocols. It is uncertain how quickly our customers will ramp-up and production volumes may fluctuate.

In 2020 the most important driver for Veoneer's business is new customer and technology launches. For the top 15 launches we see no cancellations of projects, while some have been postponed by about one quarter and the rest are on track, or actually even slightly pulled ahead of schedule. The exact volumes and consumer take rates are hard to predict at this point in time. Health and safety continue to be our first priority, and we continue to take actions to protect our associates, safeguard our operations and meet our customers' needs while managing through these unprecedented circumstances.

Associates	March 31, 2020	December 31, 2019	September 30, 2019	June 30, 2019	March 31, 2019
TOTAL	7,571	8,874	9,127	9,235	9,191
Whereof: Direct Manufacturing	1,326	2,002	2,116	2,153	2,110
RD&E	4,590	4,907	5,086	5,154	5,192
Temporary	1,166	1,396	1,630	1,659	1,563

The net number of associates decreased by 1,303 to 7,571 during the quarter as compared to 8,874 in the previous quarter. The VNBS-Asia divestiture effect of the decline was 1,074.

The underlying Veoneer decrease of 229 associates was mainly due to reductions in direct manufacturing and RD&E of 154 and 97, respectively. Temporary associates also declined during the quarter by 51 from the previous quarter. These reductions are primarily a result of our MAI actions to mitigate the impact of the COVID-19 pandemic on our business and engineering efficiency improvements.

The net number of associates decreased by 1,620 to 7,571 during the quarter from 9,191 as compared to the first quarter in 2019. The VNBS-Asia divestiture effect of the decline was 1,093.

The underlying Veoneer decrease of 527 associates was mainly due to reductions in direct manufacturing and RD&E of 262 and 377 respectively. Temporary associates also declined during the quarter by 233 as compared to the same quarter in 2019. These reductions are primarily a result of our MAIs to mitigate the COVID-19 impact on our business and engineering efficiency improvements.

2020 Outlook and Targets

Due to the market uncertainty that has been created by the COVID-19 pandemic, Veoneer is currently withdrawing its 2020 sales indication of mid-single digits organic sales growth as compared to 2019. We currently expect some launch delays during 2020, however the Company expects to outperform the global LVP in 2020, assuming no major additional launch delays.

Veoneer continues to implement additional MAIs with the goal to off-set the negative effects from lower sales and impact on cash flow. As a result of these actions, Veoneer expects cash flow before financing activities to significantly improve in 2020 as compared to 2019, and the operating loss is expected to improve in 2020 as compared to 2019, both on a comparable basis and excluding any one-time effects related to the outcome of our strategic reviews of Zenuity and Brake Control business. The Company also expects RD&E, net in 2020 to improve by approximately \$100 million as compared to 2019, on a comparable basis and capital expenditures to be less than \$150 million.

Lastly, due to the uncertain and changing market environment, as a result of the COVID-19 pandemic, it is too early for Veoneer to provide any updates regarding its 2022 Sales targets, and 2020 order intake or order book, which were previously communicated during the first quarter of 2020.

Other Topics and Events

Filings - Please refer to our Annual Report for definitions of terms used in this report. Veoneer's annual report on Form 10-K, quarterly reports on Form 10-Q, press releases, current reports on Form 8-K, proxy statement and other documents filed with the SEC can be obtained free of charge from Veoneer at the Company's address. These documents are also available at the SEC's website www.sec.gov and at Veoneer's corporate website www.veoneer.com. The earnings call webcast slide presentation is posted on our corporate website.

Reporting Structure - Veoneer is organized according to product areas around its two segments, Electronics, which includes Restraint Control Systems and Active Safety, and Brake Systems, which is the VNBS JV and our VBS US operations. Products are Veoneer's primary focus in running and reporting its business, as well as its customer focus. Consequently, although Veoneer discloses sales by region in accordance with its reporting obligations to the SEC, the Company does not believe it is particularly helpful to investors and does not intend to provide regular quarterly analysis and reporting details on sales by region or other comparisons versus light vehicle production.

February 3 - Veoneer announced the closing of the VNBS JV-Asia divestiture to Nissin Kogyo Co. Ltd. and Honda Motor Co. Ltd generating net cash proceeds of approximately \$170 million.

February 5 - Veoneer announced a new business award with an Asian based OEM which represents the eighth customer to source Veoneer for its internally developed Vision algorithms. This system award also includes Veoneer radars and software features.

Next Report - The next Veoneer earnings report for the second quarter of 2020 is currently planned for Friday, July 24, 2020. **Contacts:** Thomas Jonsson - EVP Communications & IR, thomas.jonsson@veoneer.com or +46 8 527 762 27 and Ray Pekar - VP Investor Relations, ray.pekar@veoneer.com or +1 248 794 4537.

Definitions: **ADAS** - Advanced Driver Assist Systems, **AD** - Autonomous Driving, **AGM** - Annual general Meeting, **CPV** - Content per Vehicle, **MAI** - Market Adjustment Initiatives, **LVP** - Light Vehicle Production, **OEM** - Original Equipment Manufacturer, **Order Book** - Estimated total future sales attributable to documented new business awarded, based on estimated product volumes and pricing and exchange rates, **Order Intake** - Estimated future average annual sales attributable to documented new business awarded based on estimated average annual product volumes, average annual sales price for such products, and exchange rates, **PP** - Percentage Points, **RCS** - Restraint Control Systems. **VNBS JV** - Veoneer Nissin Brake Systems Joint Venture, **VBS** - Veoneer Brake Systems.

This report is information that Veoneer, Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the EVP Communications and IR set out above, at 11:00 CET on Friday, April 24, 2020. Inquiries - Company Corporate website www.veoneer.com.

Safe Harbor Statement

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this report other than statements of historical fact, including without limitation, statements regarding management's examination of historical operating trends and data, estimates of future sales (including estimates related to order intake), RD&E spend, operating margin, cash flow, taxes or other future operating performance or financial results, are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "estimates," "expects," "anticipates," "projects," "plans," "intends," "believes," "may," "likely," "might," "would," "should," "could," or the negative of these terms and other comparable terminology, although not all forward-looking statements contain such words. We have based these forward-looking statements on our current expectations and assumptions and/or data available from third parties about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs.

New risks and uncertainties arise from time to time, and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, the following: general economic conditions; the cyclical nature of automotive sales and production; changes in general industry and market conditions or regional growth or decline; further decreases in light vehicle production; impact of COVID-19 on our customers and their production and product launch schedules; impact of COVID-19 on the Company's financial condition, business operations and liquidity; our ability to complete the transaction contemplated by the non-binding agreement with Volvo Cars and to divest VBS, which are subject to the negotiation and documentation of definitive agreements and closing; our ability to achieve the intended benefits from our separation from our former parent; our ability to be awarded new business or loss of business from increased competition; higher than anticipated costs and use of resources related to developing new technologies; higher raw material, energy and commodity costs; component shortages; changes in customer and consumer preferences for end products; market acceptance of our new products; dependence on and relationships with customers and suppliers; our ability to share RD&E costs with our customers; unfavorable fluctuations in currencies or interest rates among the various jurisdictions in which we operate; costs or difficulties related to the integration of any new or acquired businesses and technologies; successful integration of acquisitions and operations of joint ventures; successful implementation of strategic partnerships and collaborations; product liability, warranty and recall claims and investigations and other litigation and customer reactions thereto; higher expenses for our pension and other post-retirement benefits, including higher funding needs for our pension plans; work stoppages or other labor issues; possible adverse results of future litigation, regulatory actions or investigations or infringement claims; our ability to protect our intellectual property rights; tax assessments by governmental authorities and changes in our tax rate; dependence on key personnel; legislative or regulatory changes impacting or limiting our business; political conditions; and other risks and uncertainties contained in the Company's quarterly reports and Annual Report on Form 10-K.

For any forward-looking statements contained in this report or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Consolidated Income Statement

Dollars in millions, (except per share data)	Three Months Ended March 31		Last 12	Full Year
	2020	2019	Months	2019
Net sales	\$ 362	\$ 494	\$ 1,770	\$ 1,902
Cost of sales	(309)	(409)	(1,491)	(1,591)
Gross profit	53	85	279	311
Selling, general & administrative expenses	(44)	(52)	(181)	(189)
Research, development & engineering expenses, net	(131)	(156)	(537)	(562)
Amortization of intangibles	(1)	(5)	(16)	(20)
Other income / (expense), net	1	—	1	—
Operating loss	(122)	(128)	(454)	(460)
Gain / (Loss) on divestiture and assets held for sales, net	(67)	—	(67)	—
Loss from equity method investment	(18)	(17)	(71)	(70)
Interest income / (expense), net	(1)	3	4	8
Other non-operating items, net	—	—	2	1
Loss before income taxes	(208)	(142)	(586)	(521)
Income tax benefit / (expense)	(23)	(6)	(18)	(1)
Net loss¹	(231)	(148)	(604)	(522)
Less: Net Income / (loss) attributable to non-controlling interest	2	(11)	(9)	(22)
Net loss attributable to controlling interest	\$ (233)	\$ (137)	\$ (595)	\$ (500)
Net loss per share – basic²	\$ (2.09)	\$ (1.57)	\$ (5.34)	\$ (4.92)
Weighted average number of shares outstanding ²	111.47	87.24	111.47	101.62

¹ Including Corporate and other sales. ² Basic number of shares in millions used to compute net loss per share. Participating share awards without right to receive dividend equivalents are (under the two-class method) excluded from loss per share calculation.

Consolidated Balance Sheet

Dollars in millions	March 31, 2020	December 31, 2019	September 30, 2019	June 30, 2019	March 31, 2019
Assets					
Cash & cash equivalents	\$ 970	\$ 859	\$ 1,062	\$ 1,204	\$ 715
Receivables, net	216	253	309	319	364
Inventories, net	135	144	159	158	170
Related party receivables	6	11	14	16	43
Prepaid expenses and contract assets	36	47	46	42	39
Other current assets	18	18	12	19	21
Current assets held for sale	26	317	—	—	—
Total current assets	\$ 1,407	\$ 1,649	\$ 1,602	\$ 1,758	\$ 1,352
Property, plant & equipment, net	395	473	570	548	521
Right of use assets, operating lease	96	100	99	94	70
Equity method investment	79	87	75	73	81
Goodwill	289	290	290	290	290
Intangible assets, net	12	17	87	93	96
Deferred tax assets	7	7	11	10	10
Investments	10	9	10	10	8
Other non-current assets	26	111	111	91	91
Total assets	\$ 2,321	\$ 2,743	\$ 2,855	\$ 2,967	\$ 2,519
Liabilities and equity					
Accounts payable	\$ 233	\$ 233	\$ 317	\$ 276	\$ 307
Related party payables	2	3	4	12	4
Accrued expenses	198	192	227	207	214
Income tax payable	26	7	6	6	7
Other current liabilities	41	38	59	71	61
Current liabilities held for sale	7	118	—	—	—
Total current liabilities	\$ 507	\$ 591	\$ 613	\$ 572	\$ 593
4% Convertible Senior Notes due 2024	163	160	158	156	—
Pension liability	17	17	21	21	20
Deferred tax liabilities	13	13	12	12	14
Operating lease non-current liabilities	78	82	81	75	53
Financial lease non-current liabilities ¹	34	33	33	33	33
Other non-current liabilities	27	29	37	34	38
Total non-current liabilities	\$ 332	\$ 334	\$ 342	\$ 331	\$ 158
Equity					
Common stock	111	111	111	111	87
Additional paid-in capital	2,345	2,343	2,343	2,341	1,939
Accumulated deficit	(914)	(681)	(584)	(451)	(318)
Accumulated other comprehensive income (loss)	(60)	(44)	(59)	(34)	(30)
Total Equity	\$ 1,482	\$ 1,729	\$ 1,811	\$ 1,967	\$ 1,678
Non-controlling interest	—	89	89	97	90
Total Equity and non-controlling interest	\$ 1,482	\$ 1,818	\$ 1,900	\$ 2,064	\$ 1,768
Total liabilities, Equity and non-controlling interest	\$ 2,321	\$ 2,743	\$ 2,855	\$ 2,967	\$ 2,519

¹ Figures were reported as Other non-current liabilities for the last three quarters in 2018.

Consolidated Cash Flow Statement

Dollars in millions	Three Months Ended March 31		Last 12 Months	Full Year 2019
	2020	2019		
Operating activities				
Net loss	\$ (231)	\$ (148)	\$ (605)	\$ (522)
Depreciation and amortization	23	29	109	115
Net (Gain) / Loss on divestiture and assets held for sale ⁴	67	—	67	—
Change in operating assets and liabilities	116	2	138	24
Other, net	16	27	47	58
Net cash used in operating activities¹	\$ (9)	\$ (90)	\$ (244)	\$ (325)
Investing activities				
Capital expenditures	\$ (27)	\$ (59)	\$ (181)	\$ (213)
Proceeds from divestiture	176	—	176	—
Equity method investment	(16)	—	(74)	(58)
Short-term investments	—	5	—	5
Long-term investments	—	—	(1)	(1)
Proceeds from sale of property, plant and equipment	—	—	2	2
Net cash proceeds / (used) in investing activities	\$ 133	\$ (54)	\$ (78)	\$ (265)
Financing activities				
Issuance of Common Stock	\$ —	\$ —	\$ 403	\$ 403
Net increase in long-term debt	(1)	—	209	210
Net increase in short-term debt	(1)	—	21	22
Paid Dividend	(5)	—	(5)	—
Net change in related party long-term debt	—	1	—	1
Net (Decrease) / increase in related party long-term debt	—	1	(1)	—
Net cash provided by financing activities	\$ (7)	\$ 2	\$ 627	\$ 636
Effect of exchange rate changes in cash ²	(6)	(7)	(15)	(16)
(Decrease) / Increase in cash and cash equivalents	\$ 111	\$ (149)	\$ 290	\$ 30
Cash and cash equivalents at beginning of period	859	864	715	864
Less: Cash and cash equivalents at end of period, assets held for sale	—	—	(35)	(35)
Cash and cash equivalents at end of period³	\$ 970	\$ 715	\$ 970	\$ 859

¹ Operating Cash flow is the equivalent to "Net cash used in operating activities". ² Including cash equivalents. ³ Excluding Cash in Assets Held for Sale of \$35 million. ⁴ The net loss from the VNBS-Asia divestiture gain on sale of \$77 million and the VBS-US operations assets held for sale impairment of \$(144) million.

Key Ratios

Dollars in millions, (except where specified)	Three Months Ended March 31		Last 12 Months	Full Year 2019
	2020	2019		
Gross Margin % ¹	14.5	17.2	15.8	16.4
SG&A %	(12.0)	(10.5)	(10.2)	(9.9)
RD&E %	(36.1)	(31.5)	(30.3)	(29.6)
Operating Margin % ²	(33.8)	(25.9)	(25.6)	(24.2)
Depreciation and Amortization %	(6.4)	(5.8)	(10.0)	(6.1)
EBITDA % ³	(27.4)	(20.1)	(19.5)	(18.1)
Capital Expenditures %	(7.5)	(11.9)	(10.2)	(11.2)
Net Working Capital ⁴	\$ (86)	\$ 44	\$ (86)	\$ 3
Operating Cash flow ⁵	\$ (9)	\$ (90)	\$ (244)	\$ (325)
Shareholders' Equity ⁶	\$ 1,482	\$ 1,678	\$ 1,482	\$ 1,729
Cash and Cash Equivalents	\$ 970	\$ 715	\$ 970	\$ 859
Weighted average number of shares outstanding ⁶	111.47	87.24	111.47	101.62
Net loss per share – basic ⁷	\$ (2.09)	\$ (1.57)	\$ (5.34)	\$ (4.92)
Total Shareholders' Equity per share	\$ 13.30	\$ 19.23	\$ 13.30	\$ 17.01
Number of Associates at period-ending ⁸	6,405	7,628	6,405	7,478
Number of Total Associates at period-ending ⁹	7,571	9,191	7,571	8,874
Days Receivables Outstanding ¹⁰	49	67	52	52
Days Inventory Outstanding ¹¹	34	31	31	29

¹ Gross profit relative to sales. ² Operating income relative to sales. ³ See EBITDA reconciliation to net loss on page 10. ⁴ Total current assets excluding cash and cash equivalents minus total current liabilities excluding short-term debt. ⁵ Operating Cash flow is the equivalent to "Net cash used in operating activities". ⁶ Basic number of shares used to compute net loss per share in millions. Participating share awards without right to receive dividend equivalents are (under the two-class method) excluded from the loss per share calculation. ⁷ Excluding non-controlling interest. ⁸ Employees with a continuous employment agreement, recalculated to full time equivalent heads. ⁹ Includes temporary hourly personnel. ¹⁰ Outstanding receivables relative to average daily sales. ¹¹ Outstanding inventories relative to average daily sales.

Non-U.S. GAAP Financial Measures

Non-U.S. GAAP financial measures are reconciled throughout this report.

In this report we refer to organic sales or changes in organic sales growth, a non-U.S. GAAP financial measure that we, investors and analysts use to analyze the Company's sales trends and performance. We believe that this measure assists investors and management in analyzing trends in the Company's business because the Company generates approximately 68% of its sales in currencies other than in U.S. dollars (its reporting currency) and currency rates have been and can be rather volatile. The Company has historically made several acquisitions and divestitures, although none that impacted the reporting periods in question. Organic sales and organic sales growth represent the increase or decrease in the overall U.S. dollar net sales on a comparable basis, allowing separate discussions of the impact of acquisitions/divestitures and exchange rates on the Company's performance. The tables in this report present the reconciliation of changes in the total U.S. GAAP net sales to changes in organic sales growth.

The Company uses in this report EBITDA, a non-U.S. GAAP financial measure, which represents the Company's net income excluding interest expense, income taxes, depreciation and amortization and loss from equity method investment. The Company also uses Segment EBITDA, a non-U.S. GAAP financial measure, which represents the Company's EBITDA which has been further adjusted on a segment basis to exclude certain corporate and other items. We believe that EBITDA and Segment EBITDA are useful measures for management, analysts and investors to evaluate operating performance on a consolidated and reportable segment basis, because it assists in comparing our performance on a consistent basis. The tables below provide reconciliations of net income (loss) to EBITDA and Segment EBITDA.

The Company uses in this report net working capital, a non-U.S. GAAP financial measure, which is defined as current assets (excluding cash and cash equivalents) minus current liabilities excluding short-term debt and net assets and liabilities held for sale. The Company also uses in this report cash flow before financing activities, a non-U.S. GAAP financial measure, which is defined as net cash used in operating activities plus net cash used in investing activities. Management uses these measures to improve its ability to assess operating performance at a point in time as well as the trends over time. The tables below provide a reconciliation of current assets and liabilities to net working capital and cash flow before financing activities.

Investors should not consider these non-U.S. GAAP measures as substitutes, but rather as additions, to financial reporting measures prepared in accordance with U.S. GAAP. These measures, as defined, may not be comparable to similarly titled measures used by other companies.

Forward-looking non-U.S. GAAP financial measures used in this report are provided on a non-U.S. GAAP basis. Veoneer has not provided a U.S. GAAP reconciliation of these measures because items that impact these measures, such as foreign currency exchange rates and future investing activities, cannot be reasonably predicted or determined. As a result, such reconciliations are not available without unreasonable efforts and Veoneer is unable to determine the probable significance of the unavailable information.

Reconciliations of U.S. GAAP to Non-U.S. GAAP Financial Measures

Net Loss to EBITDA	Three Months Ended March 31		Last 12 Months	Full Year 2019
	2020	2019		
Dollars in millions				
Net Loss	\$ (231)	\$ (148)	\$ (605)	\$ (522)
Net (Gain) / Loss on divestiture and assets held for sale	67	—	67	—
Depreciation and amortization	23	29	110	115
Loss from equity method investment	18	17	71	70
Interest and other non-operating items, net	1	(3)	(6)	(9)
Income tax expense / (benefit)	23	6	18	1
EBITDA	\$ (99)	\$ (99)	\$ (345)	\$ (345)

Segment EBITDA to EBITDA	Three Months Ended March 31		Last 12 Months	Full Year 2019
	2020	2019		
Dollars in millions				
Electronics	\$ (72)	\$ (71)	\$ (340)	\$ (339)
Brake Systems	(12)	(10)	(81)	65
Segment EBITDA	\$ (84)	\$ (81)	\$ (421)	\$ (274)
Corporate and other	(15)	(18)	76	(71)
EBITDA	\$ (99)	\$ (99)	\$ (345)	\$ (345)

Working Capital to Net Working Capital	March 31, 2020	March 31, 2019	December 31, 2019	December 31, 2018
	Dollars in millions			
Total current assets	\$ 1,407	\$ 1,352	\$ 1,649	\$ 1,543
less Total current liabilities	507	593	591	636
Working Capital	\$ 900	\$ 759	\$ 1,058	\$ 907
less Cash and cash equivalents	(970)	(715)	(859)	(864)
less Short-term debt	3	—	3	—
less Net of Assets and Liabilities held for sale	(19)	—	(199)	—
Net Working Capital	\$ (86)	\$ 44	\$ 3	\$ 42

Cash Flow before Financing Activities	Three Months Ended March 31		Last 12 Months	Full Year 2019
	2020	2019		
Dollars in millions				
Net cash used in Operating Activities	\$ (9)	\$ (90)	\$ (244)	\$ (325)
Plus Net cash provided by (used in) Investing Activities	133	(54)	(78)	(265)
Cash flow before Financing Activities	\$ 124	\$ (144)	\$ (322)	\$ (590)